



## **Eurofins announces the successful closing of the Biomnis Group acquisition**

**15 October 2015**

Following approval from regulatory bodies, as well as completion of consultations with employee representatives, Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the successful closing of the transaction to acquire 100% of the Biomnis Group on the 14<sup>th</sup> of October, 2015.

As communicated on the 22<sup>nd</sup> of June, the Group intends to offer other prominent groups of laboratory networks in the clinical biology testing market in France the option to co-invest in Biomnis in the future. This planned partnership is in line with Eurofins' intention to closely collaborate with all the stakeholders in the French medical laboratories sector to support them in fulfilling their objective of contributing to world-class patient care in France.

Generating revenues of over EUR 220m in 2014, Biomnis is one of the largest independent esoteric laboratories in Europe focusing on specialty diagnostic testing, and should provide Eurofins a strong platform on which to deploy the competencies in specialty clinical diagnostic testing that the Group has obtained, and continues to develop, at its recently-acquired laboratories in the US. In return, Biomnis will have access to the full range of Eurofins' growing esoteric testing portfolio to further develop its leadership in specialty clinical diagnostic testing market in France, and more widely in Europe.

As part of Eurofins' plans to support Biomnis' objective to become the leading specialty clinical diagnostics testing provider in Europe, its current leader, Dr. Charles Woler and the entire Biomnis management team will remain with the company. Furthermore, the Biomnis team is pleased to welcome Mr. François Cornu, a seasoned biologist renowned in the French clinical biology market, who will be joining as President of Biomnis specialty laboratory.

**For more information about Eurofins, please visit [www.eurofins.com](http://www.eurofins.com) or contact:**

Investor Relations  
Eurofins Scientific Group  
Phone: +32 2 766 1620  
E-mail: [ir@eurofins.com](mailto:ir@eurofins.com)

### **Notes for the editor:**

#### **Eurofins – a global leader in bio-analysis**

Eurofins Scientific is the world leader in food, environment and pharmaceutical products testing. It is also one of the global market leaders in agrosience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.

With 20,000 staff in around 200 laboratories across 38 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

**Important disclaimer:**

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.